Viridian Therapeutics, Inc.\DE (VRDN) Non-Current Deffered Revenue (2021 - 2025)

Viridian Therapeutics, Inc.\DE's Non-Current Deffered Revenue history runs 5 years deep, the most recent figure standing at $140000.0 for Q2 2025.

• On a quarterly basis, Non-Current Deffered Revenue fell 67.29% year-over-year to $140000.0 in Q2 2025; TTM through Jun 2025 was $140000.0, a 67.29% decrease from a year earlier, with the FY2024 full-year figure at $284000.0, down 50.44% from the prior year.
• Non-Current Deffered Revenue fell to $140000.0 in Q2 2025 per VRDN's latest filing, from $212000.0 in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $1.1 million in Q4 2021 and bottomed at $140000.0 in Q2 2025.
• The 5-year median for Non-Current Deffered Revenue is $645000.0 (2023), against an average of $644600.0.
• Across the five-year window, Non-Current Deffered Revenue dropped 25.07% in 2022 and tumbled 67.29% in 2025, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $1.1 million in 2021, then declined by 25.07% to $861000.0 in 2022, then slumped by 33.45% to $573000.0 in 2023, then slumped by 50.44% to $284000.0 in 2024, then tumbled by 50.7% to $140000.0 in 2025.
• Per Business Quant, the three latest VRDN Non-Current Deffered Revenue figures stand at $140000.0 (Q2 2025), $212000.0 (Q1 2025), and $284000.0 (Q4 2024).